{
  "OFK.F": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ORION CORP. B",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORINF": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ORION CORPORATION",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORNAV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Orion Corporation A",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORNBV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Orion Corporation B",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  }
}
